|

Trametinib Clinical Trials

24 actively recruiting trials across 10 locations

Also known as: Closed cohort, GSK 1120212, GSK-1120212, GSK1120212, GSK1120212B +5 more

Pipeline

Phase 1: 7Phase 2: 11Phase 3: 1Phase 4: 1Phase 1/2: 3

Top Sponsors

  • Bristol-Myers Squibb2
  • Vividion Therapeutics, Inc.1
  • University of California, San Francisco1
  • University Hospital, Strasbourg, France1
  • Therapeutic Advances in Childhood Leukemia Consortium1

Indications

  • Cancer24
  • Solid Tumor2
  • Multiple Myeloma2
  • High Grade Glioma2
  • Lung Cancer2

Other13 trials

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
Phase 2
Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
Phase 2
Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas
Phase 1
Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations
Phase 2
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
Phase 1/2
Imatinib and Trametinib for KRAS-mutated Solid Tumor
Phase 1
Melanoma Metastasized to the Brain and Steroids
Phase 2
PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer
Phase 2
Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy
Phase 2
Precision Cancer Therapy in Rare Cancers
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Phase 2

Birmingham, Alabama2 trials

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

UAB Comprehensive Cancer Center

Phase 1/2
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

University of Alabama at Birmingham, Children's of Alabama

Phase 1

Huntsville, Alabama1 trial

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2

Scottsdale, Arizona1 trial

Dabrafenib and/or Trametinib Rollover Study

Honor Health Research Institute

Phase 4

Fort Smith, Arkansas1 trial

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Mercy Hospital Fort Smith

Phase 3

Duarte, California1 trial

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

City of Hope Medical Center

Phase 1

Los Angeles, California1 trial

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Children's Hospital Los Angeles

Phase 1/2

Iowa City, Iowa1 trial

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

University of Iowa

Phase 1

Boston, Massachusetts1 trial

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Massachusetts General Hospital

Phase 1

Grand Rapids, Michigan1 trial

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

START Mid West

Phase 1

Basking Ridge, New Jersey1 trial

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.